Highlight
- No statistically significant difference between mepolizumab and dupilumab in reducing moderate/severe exacerbations in eosinophilic COPD.
- Both treatments showed comparable improvements in health-related quality of life as measured by SGRQ-C.
- Matching-adjusted indirect comparison (MAIC) methodology allowed adjustment for population differences across clinical trials.
- Findings support the interchangeable clinical utility of these monoclonal antibodies targeting type 2 inflammation in COPD patients with high eosinophil counts.
Specialty calculators
For clinical reference; use professional judgment.

